OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Marc Kozin, former President of L.E.K. Consulting’s North American practice, to the Company’s Board of Directors.
“Marc has been advising healthcare companies on the growth of their businesses, technology platforms, and product lines for close to 30 years,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. "His experience helping companies develop global commercial strategies will guide us as we make AUGMENT available in IVF clinics outside the U.S. this year.”
“OvaScience’s technology has the potential to improve female fertility, and the value of its EggPC SM platform could have broader applications in other areas including human and animal health,” said Mr. Kozin. “I look forward to working with OvaScience to get innovative and much needed products to patients as soon as possible.”
Mr. Kozin has nearly 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally. Mr. Kozin served as president of the North American practice of L.E.K., a global strategy consulting firm, for 15 years and has been a Senior Advisor to L.E.K. since July 2011. He currently serves as a member of the Board of Directors of UFP Technologies, Inc., DYAX Corp., Endocyte, Inc., and three privately-held companies. He also serves on the strategic advisory board for Healthcare Royalty Partners, a global healthcare investment firm. Mr. Kozin holds a B.A., with distinction, in economics from Duke University and an M.B.A., with distinction, from The Wharton School, University of Pennsylvania.Mr. Kozin will replace Jonathan Tilly, Ph.D., a scientific co-founder of OvaScience who was recently appointed as Chair of the Department of Biology at Northeastern University. Dr. Tilly will continue to serve as a member of OvaScience’s Scientific Advisory Board.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV